Meera Mohan, Aniko Szabo, Anannya Patwari, Jean Esselmann, Tanvi Patel, Ramya Bachu, Lisa E Rein, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Catherine Skoog, Areyl Goff, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Maurizio Zangari, Nirav Shah, Frits van Rhee, Binod Dhakal, Mehdi Hamadani, Anita D'Souza, Carolina Schinke
Persistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up. Herein, we report on our multi-institutional experience of ICAHT, defined by an absolute neutrophil count (ANC) of ≤ 1000, thrombocytopenia with a platelet count ≤ 50,000 or/and anemia as hemoglobin (hgb) ≤9 g/dL, in patients who received BCMA CAR T therapy, and the effects of subsequent stem cell boost on hematopoietic reconstitution and clinical outcome...
February 15, 2024: Bone Marrow Transplantation